EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Aldo‐Keto Reductase Family 1 Member B10 as a Therapeutic Frontier: Advances in Inhibitor Design and Multimodal Approaches

Jikuan Shao, Xiaolong Wang, Can Guo, Shuaishuai Xing, Haopeng Sun iD

Medicinal Research Reviews · 2026-07 · 46 (4) · 1005-1025

DOI: 10.1002/med.70050 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 31.03.2026. Verfasst von Jikuan Shao und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China. Hauptthemen laut MEDLINE: Enzyme Inhibitors, Drug Design, Aldehyde Reductase, Aldo-Keto Reductase Family 1 member B10. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 132 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Jiangsu "333 High Level Talents Cultivation" Leading Talents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aldo‐keto reductase 1B10 (AKR1B10), a key member of the aldehyde‐ketone reductase superfamily, plays crucial roles in tumorigenesis, chemotherapy resistance, and metabolic regulation. However, the clinical translation of its inhibitors has been persistently hindered by off‐target toxicities arising from highly homologous enzymes and severe competition from intracellular substrates. This review critically summarizes the paradigm shift in AKR1B10‐targeted drug discovery. From a structural pharmacology perspective, we systematically elucidate how inhibitor design has evolved from classical anion‐binding pocket (ABP) anchoring to pocket‐specific designs that exploit the topological differences of subpockets (LAS/SP) to overcome subtype selectivity barriers. Furthermore, to bypass the inherent limitations of reversible competitive inhibition, we prospectively explore next‐generation therapeutic modalities, including targeted protein degradation (PROTACs), covalent modifiers, and small molecule–drug conjugates (SMDCs), alongside multitarget combination regimens aimed at systematically dismantling tumor resistance networks. Ultimately, this review aims to provide breakthrough insights to overcome current clinical bottlenecks, providing a reference for the future development of novel, highly efficacious precision oncology therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enzyme InhibitorsDrug DesignAldehyde ReductaseAldo-Keto Reductase Family 1 member B10Aldo-Keto ReductasesHumansAnimals

Stichwörter der Autor:innen

AKR1B10chemotherapy resistanceinhibitorsinnovative strategies

Substanzen

Enzyme InhibitorsAldehyde ReductaseAKR1B10 protein, humanAldo-Keto Reductase Family 1 member B10Aldo-Keto Reductases

Autor:innen und Institutionen

  • School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.

ORCID-Profile: Haopeng Sun

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • Jiangsu "333 High Level Talents Cultivation" Leading Talents

Zitieren

APA

Shao, J., Wang, X., Guo, C., Xing, S., & Sun, H. (2026). Aldo‐Keto Reductase Family 1 Member B10 as a Therapeutic Frontier: Advances in Inhibitor Design and Multimodal Approaches. Medicinal Research Reviews, 46(4), 1005-1025. https://doi.org/10.1002/med.70050

Vancouver

Shao J, Wang X, Guo C, Xing S, Sun H. Aldo‐Keto Reductase Family 1 Member B10 as a Therapeutic Frontier: Advances in Inhibitor Design and Multimodal Approaches. Medicinal Research Reviews. 2026;46(4):1005-1025. doi:10.1002/med.70050

BibTeX
@article{Shao2026,
  author = {Shao, Jikuan and Wang, Xiaolong and Guo, Can and Xing, Shuaishuai and Sun, Haopeng},
  title = {Aldo‐Keto Reductase Family 1 Member B10 as a Therapeutic Frontier: Advances in Inhibitor Design and Multimodal Approaches},
  journal = {Medicinal Research Reviews},
  year = {2026},
  volume = {46},
  number = {4},
  pages = {1005--1025},
  doi = {10.1002/med.70050}
}
Kostenlos starten →